Market Size of Gonorrhea Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gonorrhea Therapeutics Market Analysis
Over the next few years, the gonorrhea therapeutics market is expected to grow at a CAGR of 3.5%.
The COVID-19 pandemic impacted routine sexually transmitted infection services, suggesting an increase in syndromic sexually transmitted infections and missing asymptomatic cases. The pandemic also had a major impact on the gonorrhea therapeutics market. For instance, an article published in the February 2022 issue of the journal AANP reported that testing and treatment algorithms for sexually transmitted diseases (STDs) like gonorrhea were impacted during the pandemic due to a decrease in staffing coupled with reduced diagnostic capability and disturbances in the supply chain that led to a decrease or delay in gonorrhea diagnosis and treatment that led to an increase in gonorrhea. Thus, the COVID-19 pandemic impacted the gonorrhea therapeutics market. However, in the current scenario, with the decrease in COVID-19 cases and the resumption of healthcare services, the market is expected to witness significant growth over the forecast period.
The factors that are driving this market are the growing burden of gonorrhea and growing government and private sector participation through national campaigns. The increased number of gonorrhea cases worldwide is leading to a demand for better therapeutics, thereby driving the demand for gonorrhea therapeutics. For instance, in August 2022, WHO reported that in 2020 there were 82.4 million new cases of HIV infection among adolescents and adults aged 15-49 years worldwide, with a global incident rate of 19 per 1000 women and 23 per 1000 men. Most cases were in the African Region and the Western Pacific Region. Thus, increasing gonorrhea cases are increasing the demand for gonorrhea therapeutics and thus driving the demand for this market.
Moreover, the growing government and private sector participation in national campaigns is also fueling the growth of the studied market. For instance, in August 2022, WHO reported that the Global Health Sector Strategy on HIV, Hepatitis, and STIs (2022-2030) has set targets to reduce the number of new cases of gonorrhea among people 15-49 years old from 82.3 million per year in 2020 to 8.23 million per year in 2030, thus reducing the annual incidence by 90% by 2030. The effective prevention and control of gonococcal infections by using prevention messages, interventions, and the right treatment plans.
Similarly, in June 2022, the Australian Government, Department of Health and Aged Care, stated some fundamental guidelines to prevent gonorrhea that included knowledge of experienced professionals and providing guidance on best practices to treat gonorrhea. So, these government programs make people more aware, which increases the demand for government therapies and helps the studied market grow.
Thus, due to the growing burden of gonorrhea and growing government and private sector participation through national campaigns, the market is expected to witness significant growth over the forecast period. But strict regulations and the social stigma that comes with people going to STD clinics could slow the growth of the market that was studied.
